EPID-25. HOW MANY PATIENTS IN A REAL WORLD GLIOBLASTOMA POPULATION MEET ELIGIBILITY CRITERIA IN CLINICAL TRIALS?

In population series of glioblastoma (GBM) the median survival is < 1 year. For patients eligible for combined oncological treatment (surgery, radiotherapy (RT) and temozolomide (TMZ)) the median survival raises to 15 months. These patients are younger, have higher performance status and less com...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Skaga, Erlend, Andrea Skretteberg, Marthe, Børge Johannesen, Tom, Brandal, Petter, Osland Vik-Mo, Einar, Helseth, Eirik, Arne Langmoen, Iver
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Epidemiology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847494/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.325
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados